Isomorphic Labs, the UK-based biotech company spun out of Google DeepMind, is poised to begin human trials of drugs designed by its Nobel Prize-winning artificial intelligence. Max Jaderberg, president of Isomorphic Labs, announced at WIRED Health in London on April 16 that the startup has built a "broad and exciting pipeline of new medicines."
"We're gearing up to go into the clinic," Jaderberg said. "It's going to be a very exciting moment as we go into clinical trials and start seeing the efficacy of these molecules."
While Jaderberg did not specify a timeline, the development comes later than originally projected. Last year, CEO Demis Hassabis had stated that the company expected to have AI-designed drugs in clinical trials by the end of 2025.
Founded in 2021 as a spinoff from Alphabet's AI research subsidiary, Isomorphic Labs leverages AlphaFold, a revolutionary AI system that has transformed scientists' understanding of proteins. The platform's ability to predict protein structures is now being applied to design new medicines from scratch.
The upcoming trials mark a critical milestone for AI-driven drug discovery, as researchers and investors watch to see whether these computational designs can translate into safe and effective treatments for patients.